Loading clinical trials...
Loading clinical trials...
Hypothyroidism, defined by elevated thyrotropin (TSH) levels, is a common endocrine complication of chronic kidney disease that has been associated with impaired quality of life and cardiovascular complications. While levothyroxine is one of the most frequently prescribed medications in chronic kidney disease patients, little is known about its efficacy and safety in this population. This study will investigate 1) whether levothyroxine adequately lowers thyrotropin (TSH) levels to therapeutic target ranges, and 2) if thyroid hormone replacement improves quality of life and cardiovascular markers, without leading to wasting in dialysis patients.
Age
18 - 75 years
Sex
ALL
Healthy Volunteers
No
University Dialysis Center of Orange
Orange, California, United States
Start Date
July 1, 2017
Primary Completion Date
July 1, 2021
Completion Date
July 1, 2021
Last Updated
June 14, 2021
96
ESTIMATED participants
Levothyroxine Sodium
DRUG
Placebo Oral Tablet
DRUG
Lead Sponsor
University of California, Irvine
Collaborators
NCT04785443
NCT07217535
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07125885